Littérature scientifique sur le sujet « Triple antithrombotic therapy »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Triple antithrombotic therapy ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Triple antithrombotic therapy"
Mega, Jessica, et Edward T. Carreras. « Antithrombotic therapy : triple therapy or triple threat ? » Hematology 2012, no 1 (8 décembre 2012) : 547–52. http://dx.doi.org/10.1182/asheducation.v2012.1.547.3798919.
Texte intégralNouri, Shayan Nabavi, et Brian L. Block. « Triple Oral Antithrombotic Therapy ». JAMA Internal Medicine 176, no 10 (1 octobre 2016) : 1433. http://dx.doi.org/10.1001/jamainternmed.2016.4415.
Texte intégralVerheugt, Freek W. A. « Triple Antithrombotic Therapy After Coronary Stenting ». Circulation : Cardiovascular Interventions 4, no 5 (octobre 2011) : 410–12. http://dx.doi.org/10.1161/circinterventions.111.965210.
Texte intégralHan, Seongwook, Sola Han, Sung-Won Jang, Myung-Yong Lee, Young-Keun On, Oh Young Bang, Ji-Min Lee et al. « Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea ». Healthcare 9, no 9 (9 septembre 2021) : 1185. http://dx.doi.org/10.3390/healthcare9091185.
Texte intégralAloia, Elio, Paolo Orselli et Carlotta Sciaccaluga. « Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy : One Scenario, 8 Questions, Many Conclusions ». Current Cardiology Reviews 15, no 3 (6 mai 2019) : 219–23. http://dx.doi.org/10.2174/1573403x15666190111095438.
Texte intégralSulaica, Elisabeth M., Matthew A. Wanat et Tracy E. Macaulay. « Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy ». JAMA Cardiology 5, no 1 (1 janvier 2020) : 111. http://dx.doi.org/10.1001/jamacardio.2019.4542.
Texte intégralTuraga, Naga Sai Shravan, Danish Abbasi, Tanya Sharma et Barry Uretsky. « DOUBLE TROUBLE MANAGED WITH TRIPLE ANTITHROMBOTIC THERAPY ». Journal of the American College of Cardiology 77, no 18 (mai 2021) : 2420. http://dx.doi.org/10.1016/s0735-1097(21)03775-x.
Texte intégralFukaya, Hidehira, et Junya Ako. « Triple Antithrombotic Therapy – Always One Too Many ? – ». Circulation Journal 80, no 2 (2016) : 316–17. http://dx.doi.org/10.1253/circj.cj-15-1360.
Texte intégralSørensen, Rikke, et Gunnar Gislason. « Triple Antithrombotic Therapy : Risky but Sometimes Necessary ». Revista Española de Cardiología (English Edition) 67, no 3 (mars 2014) : 171–75. http://dx.doi.org/10.1016/j.rec.2013.08.010.
Texte intégralAytürk, Mehmet, Hamza Sunman et Ekrem Yeter. « A Persisting Dilemma for Triple Antithrombotic Therapy ». Journal of the American College of Cardiology 64, no 2 (juillet 2014) : 231. http://dx.doi.org/10.1016/j.jacc.2013.10.089.
Texte intégralThèses sur le sujet "Triple antithrombotic therapy"
Hung, Chih-Chung, et 洪智中. « Efficacy and Safety of Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting ». Thesis, 2015. http://ndltd.ncl.edu.tw/handle/9kg579.
Texte intégral高雄醫學大學
藥學系碩士在職專班
103
Background: Atrial fibrillation is a very common and severe cardiac arrhythmia which easily lead to heart blood clots to the brain ischemic stroke leading to death. Treatments of atrial fibrillation are not only to reduce cardiac symptoms, but also to prevent blood clots caused by cardiac ischemic stroke. According to ACCF/AHA/HRS therapeutic guideline, patient with high-risk (CHADS2 score≧1) can have anticoagulants to prevent stroke. Besides traditional oral Vitamin K Antagonists (Warfarin), In recent years, the development of new oral anticoagulant treatment which recommended in therapeutic guideline. Acute myocardial infarction (AMI) is a common reason for sudden cardiac death or heart failure, and the most common symptom is chest pain. When patient has MI’s symptom, he or she need to be sent to a emergency department (ED). Doctor from ED has to evaluate the reason for chest pain as soon as possible, and gives appropriate treatment in time. So far, the recommended treatments are percutaneous coronary intervention (PCI) or giving tissue plasminogen activator (tPA). Purpose: The study is base on to understand efficacy and safety with different treatments of antithrombotic agents selections that patient with atrial fibrillation and using anticoagulants has treatment after AMI occurred. Method: The study is using retrospective cohort study which included patient from 2004 to 2012 year. All patients in this study has atrial fibrillation and using anticoagulants, and they all had triple or non-triple antithrombotic agents therapy after Percutaneous coronary intervention (PCI) treatment in this hospital. Patients will use antithrombotic drugs are divided into two groups, namely the Triple oral antithrombotic therapy (TOAT group)and non- Triple oral antithrombotic therapy(NTOAT group). efficacy and safety clinical outcomes six months after the period of use of different combinations of antithrombotic drugs, such as: cerebrovascular relations events, cardiovascular events, bleeding events and time, patient mortality ,etc, whether or not a statistical difference. Results: In a retrospective study of medical records included a total of 332 patients met the criteria. And then based on the first day after admission, the clinical use of antithrombotic drugs for type divided into two groups, triple antithrombotic therapy group (TOAT group) A total of 57 patients; non-triple antithrombotic therapy group (NTOAT group) A total of 275 patients. Cardiovascular, cerebrovascular events and death as the efficacy of the two groups of patients presenting results. The case of total cardiovascular events were observed, triple therapy group 27 (47%) patients, non-triple therapy group 144 (52%) patients, the relative risk is 0.84 (95% CI 0.52-1.36), there was no statistically significant difference (p = 0.624> 0.05), in the case of cerebrovascular events were observed, the triple therapy group 7 (12%) patients, non-triple therapy group 91 (33%) patients, the relative risk is 0.33 (95% CI 0.15-0.71), the two group are statistically significant differences (P = 0.002 <0.05), and finally to the situation observed deaths, triple therapy group 12 (21 %) patients, non-triple therapy group, 103 (372%) patients, the relative risk is 0.50 (95% CI 0.27-0.91), the two are statistically significant differences (P = 0.018 <0.05), bleeding of patients as a vascular event to present safety. In the case of total bleeding events were observed, triple therapy group, 35 (62%) patients, non-triple therapy group had 123 (44%) patients, the relative risk is 1.75 (95% CI 1.75-2.85), There are statistically significant differences between the two group (P = 0.022 <0.05). Conclusion: According to the results from this study with atrial fibrillation after coronary artery stenting in these patients using oral medication triple antithrombotic effect is indeed effective in the prevention of ischemic stroke or death, but the opposite is caused by bleeding events also raised a lot, so how to increase both accurate and safe and effective use of antithrombotic drugs are currently used to assess more carefully.
Berteotti, Martina, Anna Maria Gori, Betti Giusti, Renato Valenti, Carlo Di Mario, Niccolò Marchionni et Rossella Marcucci. « Improving the net clinical benefit of dual/triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome : discovery and validation of prognostic factors for a tailored therapy ». Doctoral thesis, 2022. http://hdl.handle.net/2158/1264944.
Texte intégralChapitres de livres sur le sujet "Triple antithrombotic therapy"
« Triple antithrombotic therapy after coronary stenting for chronically anticoagulated patients : too much of a good thing ? » Dans Challenging Concepts in Cardiovascular Medicine, sous la direction de Aung Myat, Shouvik Haldar et Simon Redwood, 33–44. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199695546.003.0030.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Cardiac Chamber, Aortic, and Valvular Thromboembolism ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0009.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Plaque-Stabilizing Therapies ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0028.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Venous Thromboembolism Prophylaxis ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0030.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Platelet Antagonists ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0035.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Clopidogrel ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0013.
Texte intégralBecker, Richard C., et Frederick A. Spencer. « Acute Coronary Syndromes ». Dans Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0025.
Texte intégral« Thrombolytic/antithrombotic clinical trials in cardiology : an overview ». Dans Thrombolytic and Antithrombotic Therapy for Stroke, 74–89. CRC Press, 2004. http://dx.doi.org/10.1201/b14309-8.
Texte intégral« Study design for thrombolytic and antithrombotic treatment trials in acute stroke : mistakes and lessons ». Dans Thrombolytic and Antithrombotic Therapy for Stroke, 90–103. CRC Press, 2004. http://dx.doi.org/10.1201/b14309-9.
Texte intégralMinhas, Jatinder S., Amit K. Mistri et Thompson G. Robinson. « Secondary prevention and revascularization in the older person ». Dans Stroke in the Older Person, 353–64. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198747499.003.0023.
Texte intégralActes de conférences sur le sujet "Triple antithrombotic therapy"
Assaf, Omar, Sabeeh Shams, Aysha Basir, Tawfiq Choudhury et Kenneth Wong. « 41 Meta-analysis of clinical trials comparing triple versus dual antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes or coronary artery disease requiring percutaneous intervention ». Dans British Cardiovascular Society Virtual Annual Conference, ‘Cardiology and the Environment’, 7–10 June 2021. BMJ Publishing Group Ltd and British Cardiovascular Society, 2021. http://dx.doi.org/10.1136/heartjnl-2021-bcs.41.
Texte intégralFerreira, Hanna dos Santos, Agata Layanne Soares da Silva et João Lucas de Sousa Peres. « Fibrinolytic therapy in the treatment of pediatric ischemic stroke ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.033.
Texte intégralColleran, R., RA Byrne, H. Rai, A. Kastrati et S. Cassese. « 14 Antithrombotic therapy with or without aspirin after percutaneous coronary intervention or acute coronary syndrome in patients taking oral anticoagulation : a meta-analysis and network analysis of randomised controlled trials ». Dans Irish Cardiac Society Annual Scientific Meeting & AGM (Virtual), October 1st – 3rd 2020. BMJ Publishing Group Ltd and British Cardiovascular Society, 2020. http://dx.doi.org/10.1136/heartjnl-2020-ics.14.
Texte intégral